The association of polymorphisms in hormone metabolism pathway genes, menopausal hormone therapy, and breast cancer risk: a nested case-control study in the California Teachers Study cohort

Table 3 Single-nucleotide polymorphisms associated with breast cancer risk in postmenopausal women using estrogen-progestin therapy at baseline^a

^asingle-nucleotide polymorphisms that were associated with breast cancer risk with P values of less than 0.01 (uncorrected for multiple testing) in subgroup analyses of postmenopausal women who were using estrogen-progestin therapy at baseline. The odds ratios (ORs) and 95% confidence intervals (CIs) were based on conditional logistic regression models stratified by age group (within 5-year age groups) and specimen collection centers - the Cancer Prevention Institute of California, the University of Southern California, and the University of California at Irvine - using log-additive genetic models. ^bNumber of cases carrying 0, 1, and 2 copies of minor allele and number of controls carrying 0, 1, and 2 copies of minor allele, respectively. ^cP values not corrected for multiple testing. ^dP values for interaction with never hormone therapy (HT) users. ^eP_ACT (P value adjusted for correlated tests) was calculated within each gene by using the methods of Conneely and Boehnke [68]. ^fP_ACT was calculated across all genes by using the methods of Conneely and Boehnke [68]. CI, confidence interval; EPT, estrogen-progestin therapy; ET, estrogen-only therapy; OR, odds ratio; SNP, single-nucleotide polymorphism.

ISSN: 1465-542X